295,679 Shares in IQVIA Holdings Inc. $IQV Purchased by Man Group plc

Man Group plc purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 295,679 shares of the medical research company’s stock, valued at approximately $57,131,000.

A number of other hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC bought a new position in IQVIA in the fourth quarter worth $27,000. Compass Financial Management LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at about $27,000. CrossGen Wealth LLC bought a new stake in IQVIA in the fourth quarter valued at about $28,000. Finally, Activest Wealth Management raised its position in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last three months. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Performance

Shares of IQVIA stock opened at $259.97 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $261.88. The firm has a market cap of $42.79 billion, a P/E ratio of 32.25, a P/E/G ratio of 2.21 and a beta of 1.18. The firm has a 50 day simple moving average of $216.59 and a 200 day simple moving average of $188.02.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company earned $2.81 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Mizuho lifted their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. HSBC reissued a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. TD Cowen upped their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Robert W. Baird lifted their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.